Castle Biosciences, Inc.

CSTL Healthcare Diagnostics & Research

Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS fell 143.8%, free cash flow fell 43.3% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

31.96 1.84 −5.44%
Market cap
$1.0B
P/E
0.0×
Fwd P/E
−15.2×
Dividend yield
—
F-score
3/9
Altman Z
6.70
Beneish M
−3.49
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
1.93 3.28 2.16 2.03
P/FCF ratio
26.04 39.74 160.88 0.00
P/Operating CF
29.25 41.87 (33.16) 47.70
P/B ratio
1.42 2.39 1.59 1.54
Price to Tangible BV
1.81 3.04 2.02 1.93
EV/Sales
1.13 2.44 1.42 1.31
EV/EBITDA
142.99 0.00 0.00 0.00
EV/Operating CF
6.26 13.03 10.00 10.99
EV/FCF
15.21 29.55 105.78 (1,036.62)
Quick Ratio
6.09 4.99 6.23 5.58
Current Ratio
6.47 5.26 6.75 6.04
Net Debt/EBITDA
71.19 381.44 16.83 (421.82)
Debt/Assets
1.85% 1.79% 1.89% 1.84%
Debt/Equity
0.02 0.02 0.02 0.02
Asset Turnover
0.64 0.62 0.65 0.65
Operating CF/Net income
(45.17) (11.55) 1.52 (7.38)
Capex/Depreciation
(5.09) (2.34) (3.58) (2.35)
Interest Coverage
(283.50) (159.46) (137.37) (15.91)
Research and Development Expense of Revenue
15.61% 15.53% 17.24% 14.04%
Selling, General and Administrative Expense of Revenue
67.32% 65.20% 77.56% 63.86%
Intangible Assets out of Total Assets
0.18 0.17 0.18 0.17
Share Based Compensation of Revenue
14.57% 13.11% 11.68% 11.19%
Graham Net Nets
0.40 0.22 0.33 0.34
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(1.84%) (2.16%) (1.75%) (2.77%)
Free Cash Flow Yield
3.84% 2.52% 0.62% (0.06%)
Revenue per Share
2.86 3.00 2.80 3.41
Operating CF per Share
0.78 0.93 (0.74) 0.50
Capex per Share
(0.51) (0.25) (0.42) (0.28)
Free Cash Flow per Share
0.27 0.68 (1.16) 0.22
Cash per Share
9.89 10.33 8.76 8.78
Shareholders Equity per Share
16.06 16.24 15.44 15.46
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
16.06 16.24 15.44 15.46
Free Cash Flow
7.82 19.75 (34.58) 6.56
Working Capital
302.26 292.42 280.14 284.59
Capital Expenditures
(14.81) (7.18) (12.45) (8.64)
Net Current Asset Value
261.83 253.41 242.51 249.95
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.18 0.08 0.15 0.08
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
49.87 47.30 49.31 50.33
Average Payables
9.51 12.81 11.77 11.42
Average Inventory
7.61 9.19 8.66 9.47
Average Assets
538.68 554.90 524.76 552.95
Average Common Equity
454.05 463.35 450.86 462.70

Fold the line items

Columns are period end dates